Structure-Activity Relationship Study of Heterocyclic Phenylethenyl and Pyridinylethenyl Derivatives as Tau-Imaging Agents That Selectively Detect Neurofibrillary Tangles in Alzheimers Disease Brains

Journal of Medicinal Chemistry

Volumn 58, Issue 18, 2015, Pages 7241-7257

  Matsumura, Kenji ^a   Ono, Masahiro ^a   Kitada, Ayane ^a   Watanabe, Hiroyuki ^a   Yoshimura, Masashi ^a   Iikuni, Shimpei ^a   Kimura, Hiroyuki ^a   Okamoto, Yoko ^b   Ihara, Masafumi ^b   Saji, Hideo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 IODO 2 STYRYL 1H BENZO[D]IMIDAZOLE; 6 IODO 2 STYRYL 1H BENZO[D]IMIDAZOLE I 125; BENZIMIDAZOLE DERIVATIVE; HETEROCYCLIC COMPOUND; IODINE 125; PHENYLETHENYL DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDINYLETHENYL DERIVATIVE; TAU PROTEIN; UNCLASSIFIED DRUG; 6-IODO-2-STYRYL-1H-BENZO(D)IMIDAZOLE; AMYLOID BETA PROTEIN; BENZOFURAN DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; BENZOXAZOLE DERIVATIVE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; STYRENE DERIVATIVE; THIOPHENE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; RADIOACTIVITY; STRUCTURE ACTIVITY RELATION; TEMPORAL LOBE; AGED; ANIMAL; BRAIN; CHEMISTRY; MALE; METABOLISM; PATHOLOGY; SCINTISCANNING; STEREOISOMERISM; SYNTHESIS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AUTORADIOGRAPHY; BENZIMIDAZOLES; BENZOFURANS; BENZOTHIAZOLES; BENZOXAZOLES; BRAIN; HUMANS; IODINE RADIOISOTOPES; MALE; MICE; NEUROFIBRILLARY TANGLES; PYRIDINES; RADIOPHARMACEUTICALS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; STYRENES; TAU PROTEINS; TEMPORAL LOBE; THIOPHENES;

EID: 84942305817     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00440     Document Type: Article

References (52)

1. Brookmeyer, R.; Johnson, E.; Ziegler-Graham, K.; Arrighi, H. M. Forecasting the global burden of Alzheimers disease Alzheimer's Dementia 2007, 3, 186-191 10.1016/j.jalz.2007.04.381
2. Felsenstein, K. M.; Candelario, K. M.; Steindler, D. A.; Borchelt, D. R. Regenerative medicine in Alzheimers disease Transl Res. 2014, 163, 432-438 10.1016/j.trsl.2013.11.001
3. Jack, C. R., Jr.; Knopman, D. S.; Jagust, W. J.; Shaw, L. M.; Aisen, P. S.; Weiner, M. W.; Petersen, R. C.; Trojanowski, J. Q. Hypothetical model of dynamic biomarkers of the Alzheimers pathological cascade Lancet Neurol. 2010, 9, 119-128 10.1016/S1474-4422(09)70299-6
4. Mathis, C. A.; Mason, N. S.; Lopresti, B. J.; Klunk, W. E. Development of positron emission tomography β-amyloid plaque imaging agents Semin. Nucl. Med. 2012, 42, 423-432 10.1053/j.semnuclmed.2012.07.001
5. 11C-labeled stilbene derivatives as Aβ-aggregate-specific PET imaging agents for Alzheimers disease Nucl. Med. Biol. 2003, 30, 565-571 10.1016/S0969-8051(03)00049-0
6. Furukawa, K.; Okamura, N.; Tashiro, M.; Waragai, M.; Furumoto, S.; Iwata, R.; Yanai, K.; Kudo, Y.; Arai, H. Amyloid PET in mild cognitive impairment and Alzheimers disease with BF-227: comparison to FDG-PET J. Neurol. 2010, 257, 721-727 10.1007/s00415-009-5396-8
7. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial Ann. Neurol. 2010, 68, 319-329 10.1002/ana.22068
8. 18F stilbenes and styrylpyridines for PET imaging of Aβ plaques in Alzheimers disease: a miniperspective J. Med. Chem. 2010, 53, 933-941 10.1021/jm901039z
9. Clark, C. M.; Schneider, J. A.; Bedell, B. J.; Beach, T. G.; Bilker, W. B.; Mintun, M. A.; Pontecorvo, M. J.; Hefti, F.; Carpenter, A. P.; Flitter, M. L.; Krautkramer, M. J.; Kung, H. F.; Coleman, R. E.; Doraiswamy, P. M.; Fleisher, A. S.; Sabbagh, M. N.; Sadowsky, C. H.; Reiman, E. P.; Zehntner, S. P.; Skovronsky, D. M.; Group, A. A. S. Use of florbetapir-PET for imaging β-amyloid pathology JAMA 2011, 305, 275-283 10.1001/jama.2010.2008
10. Kung, M. P.; Hou, C.; Zhuang, Z. P.; Zhang, B.; Skovronsky, D.; Trojanowski, J. Q.; Lee, V. M.; Kung, H. F. IMPY: an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques Brain Res. 2002, 956, 202-210 10.1016/S0006-8993(02)03436-4
11. 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia J. Nucl. Med. 2013, 54, 880-886 10.2967/jnumed.112.114785
12. Yousefi, B. H.; Manook, A.; Grimmer, T.; Arzberger, T.; von Reutern, B.; Henriksen, G.; Drzezga, A.; Forster, S.; Schwaiger, M.; Wester, H. J. Characterization and first human investigation of FIBT, a novel fluorinated Aβ plaque neuroimaging PET radioligand ACS Chem. Neurosci. 2015, 6, 428-437 10.1021/cn5001827
13. Jack, C. R., Jr.; Lowe, V. J.; Weigand, S. D.; Wiste, H. J.; Senjem, M. L.; Knopman, D. S.; Shiung, M. M.; Gunter, J. L.; Boeve, B. F.; Kemp, B. J.; Weiner, M.; Petersen, R. C. Alzheimers Disease Neuroimaging, I. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: implications for sequence of pathological events in Alzheimers disease Brain 2009, 132, 1355-1365 10.1093/brain/awp062
14. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease Neurology 2006, 67, 446-452 10.1212/01.wnl.0000228230.26044.a4
15. Aizenstein, H. J.; Nebes, R. D.; Saxton, J. A.; Price, J. C.; Mathis, C. A.; Tsopelas, N. D.; Ziolko, S. K.; James, J. A.; Snitz, B. E.; Houck, P. R.; Bi, W.; Cohen, A. D.; Lopresti, B. J.; DeKosky, S. T.; Halligan, E. M.; Klunk, W. E. Frequent amyloid deposition without significant cognitive impairment among the elderly Arch. Neurol. 2008, 65, 1509-1517 10.1001/archneur.65.11.1509
16. Citron, M. Alzheimers disease: strategies for disease modification Nat. Rev. Drug Discovery 2010, 9, 387-398 10.1038/nrd2896
17. Mullard, A. Sting of Alzheimers failures offset by upcoming prevention trials Nat. Rev. Drug Discovery 2012, 11, 657-660 10.1038/nrd3842
18. Gilman, S.; Koller, M.; Black, R. S.; Jenkins, L.; Griffith, S. G.; Fox, N. C.; Eisner, L.; Kirby, L.; Rovira, M. B.; Forette, F.; Orgogozo, J. M.; Team, A. N. S. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial Neurology 2005, 64, 1553-1562 10.1212/01.WNL.0000159740.16984.3C
19. 42 immunisation in Alzheimers disease: follow-up of a randomised, placebo-controlled phase I trial Lancet 2008, 372, 216-223 10.1016/S0140-6736(08)61075-2
20. Jack, C. R., Jr.; Knopman, D. S.; Jagust, W. J.; Petersen, R. C.; Weiner, M. W.; Aisen, P. S.; Shaw, L. M.; Vemuri, P.; Wiste, H. J.; Weigand, S. D.; Lesnick, T. G.; Pankratz, V. S.; Donohue, M. C.; Trojanowski, J. Q. Tracking pathophysiological processes in Alzheimers disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol. 2013, 12, 207-216 10.1016/S1474-4422(12)70291-0
21. Shaw, L. M.; Vanderstichele, H.; Knapik-Czajka, M.; Clark, C. M.; Aisen, P. S.; Petersen, R. C.; Blennow, K.; Soares, H.; Simon, A.; Lewczuk, P.; Dean, R.; Siemers, E.; Potter, W.; Lee, V. M.; Trojanowski, J. Q. Alzheimers Disease Neuroimaging, I. Cerebrospinal fluid biomarker signature in Alzheimers disease neuroimaging initiative subjects Ann. Neurol. 2009, 65, 403-413 10.1002/ana.21610
22. Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes Acta Neuropathol. 1991, 82, 239-259 10.1007/BF00308809
23. Delacourte, A.; David, J. P.; Sergeant, N.; Buee, L.; Wattez, A.; Vermersch, P.; Ghozali, F.; Fallet-Bianco, C.; Pasquier, F.; Lebert, F.; Petit, H.; Di Menza, C. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimers disease Neurology 1999, 52, 1158-1165 10.1212/WNL.52.6.1158
24. Gomez-Isla, T.; Hollister, R.; West, H.; Mui, S.; Growdon, J. H.; Petersen, R. C.; Parisi, J. E.; Hyman, B. T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimers disease Ann. Neurol. 1997, 41, 17-24 10.1002/ana.410410106
25. Nelson, P. T.; Alafuzoff, I.; Bigio, E. H.; Bouras, C.; Braak, H.; Cairns, N. J.; Castellani, R. J.; Crain, B. J.; Davies, P.; Del Tredici, K.; Duyckaerts, C.; Frosch, M. P.; Haroutunian, V.; Hof, P. R.; Hulette, C. M.; Hyman, B. T.; Iwatsubo, T.; Jellinger, K. A.; Jicha, G. A.; Kovari, E.; Kukull, W. A.; Leverenz, J. B.; Love, S.; Mackenzie, I. R.; Mann, D. M.; Masliah, E.; McKee, A. C.; Montine, T. J.; Morris, J. C.; Schneider, J. A.; Sonnen, J. A.; Thal, D. R.; Trojanowski, J. Q.; Troncoso, J. C.; Wisniewski, T.; Woltjer, R. L.; Beach, T. G. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature J. Neuropathol. Exp. Neurol. 2012, 71, 362-381 10.1097/NEN.0b013e31825018f7
26. Whitwell, J. L.; Josephs, K. A.; Murray, M. E.; Kantarci, K.; Przybelski, S. A.; Weigand, S. D.; Vemuri, P.; Senjem, M. L.; Parisi, J. E.; Knopman, D. S.; Boeve, B. F.; Petersen, R. C.; Dickson, D. W.; Jack, C. R., Jr. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study Neurology 2008, 71, 743-749 10.1212/01.wnl.0000324924.91351.7d
27. 18F-THK5105 PET Brain 2014, 137, 1762-1771 10.1093/brain/awu064
28. 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease J. Nucl. Med. 2013, 54, 1420-1427 10.2967/jnumed.112.117341
29. 18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimers disease Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 1052-1061 10.1007/s00259-015-3035-4
30. 18F]T807, a novel tau positron emission tomography imaging agent for Alzheimers disease Alzheimer's Dementia 2013, 9, 666-676 10.1016/j.jalz.2012.11.008
31. Chien, D. T.; Bahri, S.; Szardenings, A. K.; Walsh, J. C.; Mu, F.; Su, M. Y.; Shankle, W. R.; Elizarov, A.; Kolb, H. C. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807 J. Alzheimers Dis 2013, 34, 457-468 10.3233/JAD-122059
32. Chien, D. T.; Szardenings, A. K.; Bahri, S.; Walsh, J. C.; Mu, F.; Xia, C.; Shankle, W. R.; Lerner, A. J.; Su, M. Y.; Elizarov, A.; Kolb, H. C. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808 J. Alzheimers Dis 2014, 38, 171-184 10.3233/JAD-130098
33. Zhang, W.; Arteaga, J.; Cashion, D. K.; Chen, G.; Gangadharmath, U.; Gomez, L. F.; Kasi, D.; Lam, C.; Liang, Q.; Liu, C.; Mocharla, V. P.; Mu, F.; Sinha, A.; Szardenings, A. K.; Wang, E.; Walsh, J. C.; Xia, C.; Yu, C.; Zhao, T.; Kolb, H. C. A highly selective and specific PET tracer for imaging of tau pathologies J. Alzheimers Dis 2012, 31, 601-612 10.3233/JAD-2012-120712
34. Maruyama, M.; Shimada, H.; Suhara, T.; Shinotoh, H.; Ji, B.; Maeda, J.; Zhang, M. R.; Trojanowski, J. Q.; Lee, V. M.; Ono, M.; Masamoto, K.; Takano, H.; Sahara, N.; Iwata, N.; Okamura, N.; Furumoto, S.; Kudo, Y.; Chang, Q.; Saido, T. C.; Takashima, A.; Lewis, J.; Jang, M. K.; Aoki, I.; Ito, H.; Higuchi, M. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls Neuron 2013, 79, 1094-1108 10.1016/j.neuron.2013.07.037
35. 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology J. Nucl. Med. 2014, 55, 1532-1538 10.2967/jnumed.114.139550
36. 11C]N-Methyl Lansoprazole as a Radiopharmaceutical for PET Imaging of Tau Neurofibrillary Tangles ACS Med. Chem. Lett. 2012, 3, 936-941 10.1021/ml300216t
37. Fawaz, M. V.; Brooks, A. F.; Rodnick, M. E.; Carpenter, G. M.; Shao, X.; Desmond, T. J.; Sherman, P.; Quesada, C. A.; Hockley, B. G.; Kilbourn, M. R.; Albin, R. L.; Frey, K. A.; Scott, P. J. High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimers disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection ACS Chem. Neurosci. 2014, 5, 718-730 10.1021/cn500103u
38. Riss, P.; Brichard, L.; Ferrari, V.; Williamson, D.; Fryer, T.; Hong, Y.; Baron, J.; Aigbirhio, F. Radiosynthesis and characterization of astemizole derivatives as lead compounds toward PET imaging of -pathology MedChemComm 2013, 4, 852-855 10.1039/c3md00017f
39. Ono, M.; Hayashi, S.; Matsumura, K.; Kimura, H.; Okamoto, Y.; Ihara, M.; Takahashi, R.; Mori, H.; Saji, H. Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimers brains ACS Chem. Neurosci. 2011, 2, 269-275 10.1021/cn200002t
40. Watanabe, H.; Ono, M.; Kimura, H.; Matsumura, K.; Yoshimura, M.; Okamoto, Y.; Ihara, M.; Takahashi, R.; Saji, H. Synthesis and biological evaluation of novel oxindole derivatives for imaging neurofibrillary tangles in Alzheimers disease Bioorg. Med. Chem. Lett. 2012, 22, 5700-5703 10.1016/j.bmcl.2012.06.086
41. Matsumura, K.; Ono, M.; Hayashi, H.; Kimura, H.; Okamoto, Y.; Ihara, M.; Takahashi, K.; Mori, H.; Saji, H. Phenyldiazenyl benzothiazole derivatives as probes for in vivo imaging of neurofibrillary tangles in Alzheimers disease brains MedChemComm 2011, 2, 596-600 10.1039/c1md00034a
42. Matsumura, K.; Ono, M.; Yoshimura, M.; Kimura, H.; Watanabe, H.; Okamoto, Y.; Ihara, M.; Takahashi, R.; Saji, H. Synthesis and biological evaluation of novel styryl benzimidazole derivatives as probes for imaging of neurofibrillary tangles in Alzheimers disease Bioorg. Med. Chem. 2013, 21, 3356-3362 10.1016/j.bmc.2013.02.054
43. 123I-labeled pyridyl benzoxazole derivatives: novel β-amyloid imaging probes for single-photon emission computed tomography RSC Adv. 2015, 5, 1009-1015 10.1039/C4RA10742J
44. 123I-labeled pyridyl benzofuran derivatives for SPECT imaging of β-amyloid plaques in Alzheimers disease PLoS One 2013, 8, e74104 10.1371/journal.pone.0074104
45. Mishra, A.; Thangamani, A.; Chatterjee, S.; Chipem, F. A.; Krishnamoorthy, G. Photoisomerization of trans-2-[4′-(dimethylamino)styryl]benzothiazole Photochem. Photobiol. 2013, 89, 247-252 10.1111/j.1751-1097.2012.01227.x
46. Lewis, F. D.; Yoon, B. A.; Arai, T.; Iwasaki, T.; Tokumatsu, K. Molecular structure and photochemistry of (E)- and (Z)-2-(2-(2-pyridyl)ethenyl)indole. A case of hydrogen bond dependent one-way photoisomerization J. Am. Chem. Soc. 1995, 117, 3029-3036 10.1021/ja00116a008
47. Rojo, L. E.; Alzate-Morales, J.; Saavedra, I. N.; Davies, P.; Maccioni, R. B. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimers disease J. Alzheimers Dis 2010, 19, 573-589 10.3233/JAD-2010-1262
48. Honson, N. S.; Johnson, R. L.; Huang, W.; Inglese, J.; Austin, C. P.; Kuret, J. Differentiating Alzheimer disease-associated aggregates with small molecules Neurobiol. Dis. 2007, 28, 251-260 10.1016/j.nbd.2007.07.018
49. Okamura, N.; Suemoto, T.; Furumoto, S.; Suzuki, M.; Shimadzu, H.; Akatsu, H.; Yamamoto, T.; Fujiwara, H.; Nemoto, M.; Maruyama, M.; Arai, H.; Yanai, K.; Sawada, T.; Kudo, Y. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimers disease J. Neurosci. 2005, 25, 10857-10862 10.1523/JNEUROSCI.1738-05.2005
50. Harada, R.; Okamura, N.; Furumoto, S.; Yoshikawa, T.; Arai, H.; Yanai, K.; Kudo, Y. Use of a benzimidazole derivative BF-188 in fluorescence multispectral imaging for selective visualization of tau protein fibrils in the Alzheimers disease brain Mol. Imaging Biol. 2014, 16, 19-27 10.1007/s11307-013-0667-2
51. Pike, V. W. PET radiotracers: crossing the blood-brain barrier and surviving metabolism Trends Pharmacol. Sci. 2009, 30, 431-440 10.1016/j.tips.2009.05.005
52. 18F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimers disease Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 1784-1795 10.1007/s00259-012-2178-9